Emiltatug ledadotin (Emi-Le)

Name: Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Dosage forms and strengths
Published: 2026-09-17T22:01:26-04:00

Adenoid cystic carcinoma with solid histology or high-grade transformation

Also known as XMT-1660

Manufacturer: Servier
Regulatory submission: Not announced
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Dosage forms and strengths

2 evidence topics · 2 sources

Route of administration in clinical trials

“Emi-Le will be administered through a vein in your arm or port catheter (intravenously)” (opens the source at this quote in a new tab)

Dosing units used in clinical trials

“Across dose escalation and backfill, eligible pts received Emi-Le at doses of 7.2–115 mg/m2 IV per Q3W or Q4W cycle.” (opens the source at this quote in a new tab)

Formulation, vial strength, and storage

No evidence found.